U.S. Markets closed

Merck To Acquire Cancer Biotech In Deal Worth Up To $2.2 Billion

ALLISON GATLIN
Merck To Acquire Cancer Biotech In Deal Worth Up To $2.2 Billion

Dow Jones component Merck will spend up to $2.2 billion to buy privately held biotech Peloton Therapeutics for its cancer treatments. Peloton's latest-stage effort is a kidney cancer drug.